Differential trapping of PARP1 and PARP2 by clinical PARP inhibitors
Explore this paper's citation graph
Summary
It is demonstrated that PARP inhibitors trap the PARP1 and PARP2 enzymes at damaged DNA, providing a new mechanistic foundation for the rational application of PARP inhibitors in cancer therapy.
- Type
- article
- Published
- 2012-11-01
- Cited by
- 1,887
- References
- 53
- Access
- Open access
- OpenAlex
- https://openalex.org/W2098737737
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:13779484
Keywords
Veliparib, Olaparib, PARP1, Poly ADP ribose polymerase, DNA repair
References
- Roles of sequential ubiquitination of PCNA in DNA‐damage tolerance
- ADP-ribosylation in mammalian cell ghosts. Dependence of poly(ADP-ribose) synthesis on strand breakage in DNA.
- The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases.
- Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse
- Poly(ADP-ribose) Polymerase Activity Prevents Signaling Pathways for Cell Cycle Arrest after DNA Methylating Agent Exposure*
- Role of poly(ADP-ribose) formation in DNA repair
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
- Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks.
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
- Dynamic regulation of PCNA ubiquitylation/deubiquitylation
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
- Poly(ADP-ribose) levels in carcinogen-treated cells
- Targeted therapy for cancer using PARP inhibitors.
- Involvement of Poly(ADP-ribose) Polymerase-1 and XRCC1/DNA Ligase III in an Alternative Route for DNA Double-strand Breaks Rejoining*
- Poly(ADP-ribose) polymerase and XPF–ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells
- PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase*
- Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
- Quality control by DNA repair.
Cited by
- Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
- What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
- PARP inhibitors: the race is on
- Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.
- Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
- The rise of genomic profiling in ovarian cancer
- Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
- PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy
- Restricted delivery of talazoparib across the blood-brain barrier limits the sensitizing effects of poly (ADP-ribose) polymerase inhibition on temozolomide therapy in glioblastoma
- Talazoparib is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
- Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
- Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways.
- PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers.
- Micro-irradiation tools to visualize base excision repair and single-strand break repair
- The global cancer genomics consortium's symposium: new era of molecular medicine and epigenetic cancer medicine - cross section of genomics and epigenetics
- Identification and mechanism of action analysis of the new PARP-1 inhibitor 2″-hydroxygenkwanol A.
- Analysis of haploinsufficiency in women carrying germline mutations in the BRCA1 gene: Different mutations, different phenotypes ?
- New Biologic Frontiers in Ovarian Cancer: Olaparib and PARP Inhibition
- Role of PARP-1 in prostate cancer.
- Characterization and Quantification of Poly(ADP-Ribose) in Cells and Tissues by Isotope Dilution Mass Spectrometry
Related papers
- Abstract 3421: Differential potentiation of temozolomide and camptothecin by the PARP inhibitors olaparib and veliparib in relationship with their PARP-DNA trapping abilities, and lack of impact of PARP inhibitors on cisplatin activity.
- Abstract 2965: Olaparib and veliparib as effective PARP inhibitors for cancer prevention in a BRCA1-deficient mouse model
- An Overview of PARP Inhibitors for the Treatment of Breast Cancer
- The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
- Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.
- The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice
- Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
- Selectivity profile of the poly(ADP-ribose) polymerase (PARP) inhibitor, A-966492
- Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination proficient pancreatic cancer